Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Losartan
Drug ID BADD_D01322
Description Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored.[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]
Indications and Usage May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Marketing Status Prescription; Discontinued
ATC Code C09CA01
DrugBank ID DB00678
KEGG ID D08146
MeSH ID D019808
PubChem ID 3961
TTD Drug ID D0DD0K
NDC Product Code Not Available
Synonyms Losartan | 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol | DuP-753 | DuP 753 | DuP753 | MK-954 | MK 954 | MK954 | Cozaar | Losartan Potassium | Potassium, Losartan | Losartan Monopotassium Salt | Monopotassium Salt, Losartan | Salt, Losartan Monopotassium
Chemical Information
Molecular Formula C22H23ClN6O
CAS Registry Number 114798-26-4
SMILES CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Capillary fragility increasedC-C motif chemokine 2P14844Not Available26156105
Capillary fragility increasedInterleukin-1 alphaP01583T1634026156105
Capillary fragility increasedInterleukin-10P29456Not Available26156105
Metabolic disorderCytochrome P450 2C9P11712T192449663807; 11434505; 9825828
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood pressure systolic increased13.14.03.0060.000146%Not Available
Blood thyroid stimulating hormone increased13.10.03.0060.000049%
Blood urea abnormal13.13.01.0050.000049%Not Available
Blood urea increased13.13.01.0060.000097%Not Available
Blood uric acid increased13.02.04.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bone pain15.02.01.0010.000315%
Bradycardia02.03.02.002--Not Available
Breast cancer21.05.01.003; 16.10.01.0010.000170%Not Available
Breast mass21.05.04.0020.000049%Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Burning sensation17.02.06.001; 08.01.09.0290.000194%Not Available
Cachexia16.32.03.011; 14.03.02.001; 08.01.01.0090.000019%Not Available
Carbon dioxide decreased13.02.01.0120.000049%Not Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.001--
Cardiac failure congestive02.05.01.002--Not Available
Cardiac tamponade02.06.01.0010.000013%
Cardio-respiratory arrest22.02.06.007; 02.03.04.002--Not Available
Cardiogenic shock02.05.01.003; 24.06.02.006--Not Available
Cardiomyopathy02.04.01.0010.000097%Not Available
Cataract06.06.01.001--
Cellulitis11.02.01.001; 23.09.01.0010.000170%Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.003--Not Available
Cerebral ischaemia17.08.01.005; 24.04.06.0030.000073%
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Cerebrovascular disorder17.08.02.002; 24.03.05.0020.000073%Not Available
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.0090.000243%Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.001--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 19 Pages